Monday, May 07, 2007 12:47:07 AM
*CELG reports Q1 EPS of 20c vs. consensus of 21c
Reports Q1 revenue of $293.41M vs. consensus of $294.54M. The company sees 2007 EPS of approximately $1.00 vs. consensus of $1.04 and revenue in the $1.3B range vs. consensus of $1.35B.
1Q07 EPS missed estimate and was in-line with consensus-Neut@BARD
The Revlimid launch was strong and the firm views it as being priced into the stock. Remains sidelined with their new $57 price target.
target upped to $72 from $70 on projected earnings growth-Buy@LAZA
LAZA increased its target to $72 from $70 and believes the 1.7 PEG and the three year period are warranted given Celgene's projected earnings growth through what the firm argues is a mature phase of Revlimid's launch. :
>
Reports Q1 revenue of $293.41M vs. consensus of $294.54M. The company sees 2007 EPS of approximately $1.00 vs. consensus of $1.04 and revenue in the $1.3B range vs. consensus of $1.35B.
1Q07 EPS missed estimate and was in-line with consensus-Neut@BARD
The Revlimid launch was strong and the firm views it as being priced into the stock. Remains sidelined with their new $57 price target.
target upped to $72 from $70 on projected earnings growth-Buy@LAZA
LAZA increased its target to $72 from $70 and believes the 1.7 PEG and the three year period are warranted given Celgene's projected earnings growth through what the firm argues is a mature phase of Revlimid's launch. :
>
Know how to make God laugh?
Tell Her your plans ....
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
